Lanreotid Sun (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors SSTR2 and SSTR5 on target cells. This binding blocks adenylate cyclase, lowers cyclic AMP, and suppresses the release of growth hormone and other peptide hormones, thereby controlling disease activity.

The specific dose and dosing interval of Lanreotid Sun are determined by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber will select the appropriate regimen from the approved dosing options.

Safety data for lanreotide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Lanreotid Sun is comparable to other long‑acting somatostatin analogs such as octreotide LAR. All share a similar mechanism of receptor binding, but differences exist in dosing frequency, formulation stability, and individual patient tolerability, which the clinician will consider when selecting therapy.

Lanreotid Sun should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain potency and sterility.

Lanreotid Sun is administered by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a healthcare professional or trained patient following aseptic technique and the specific administration instructions provided by the prescriber.

Serious risks include the development of gallstones or biliary colic, acute pancreatitis, severe hyperglycaemia that may require medical intervention, and rare allergic reactions such as anaphylaxis. Patients should be monitored regularly for these events.

Lanreotid Sun is contraindicated in patients with known hypersensitivity to lanreotide or any excipients in the formulation. Caution is advised for individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease, and the drug should be avoided in such cases unless benefits outweigh risks.